Research Article Evaluation of CERS2 Gene as a Potential Biomarker for Bladder Cancer Ahmed Faris Aldoghachi, 1 Aminuddin Baharudin , 1 Umar Ahmad , 1 Soon Choy Chan, 2 Teng Aik Ong, 3 Rosna Yunus, 4 Azad Hassan Razack, 3 Khatijah Yusoff , 5,6 and Abhi Veerakumarasivam 1,6,7 1 Medical Genetics Laboratory, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor Darul Ehsan, Malaysia 2 Perdana University School of Foundation Studies, Perdana University, Selangor Darul Ehsan, Malaysia 3 Department of Surgery, Faculty of Medicine, University of Malaya, Wilayah Persekutuan, Kuala Lumpur, Malaysia 4 Histopathology Unit, Department of Pathology, Hospital Kuala Lumpur, Wilayah Persekutuan, Kuala Lumpur, Malaysia 5 Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, Selangor Darul Ehsan, Malaysia 6 Malaysia Genome Institute, National Institute of Biotechnology Malaysia, Selangor Darul Ehsan, Malaysia 7 Department of Biological Sciences, School of Science and Technology, Sunway University, Selangor Darul Ehsan, Malaysia Correspondence should be addressed to Abhi Veerakumarasivam; abhiv@sunway.edu.my Received 16 November 2018; Revised 11 February 2019; Accepted 26 February 2019; Published 15 September 2019 Academic Editor: Tilman Todenhöfer Copyright © 2019 Ahmed Faris Aldoghachi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The ceramide synthase 2 (CERS2) gene has been linked to tumour recurrence and invasion in many different types of cancers including bladder cancer. In this study, the expression levels of CERS2 in bladder cancer cell lines were analysed using qRT-PCR and the protein expression in clinical bladder cancer histopathological specimens were examined via immunohistochemistry. The potential utility of CERS2 as a predictive biomarker of response to oncolytic virotherapy was assessed by correlating the CERS2 mRNA expression to IC 50 values of cells treated with the Newcastle disease virus (NDV), AF2240 strain. This study demonstrates that CERS2 is differentially expressed in different types of bladder cancer cell lines and that the siRNA-mediated downregulation of the expression of CERS2 reduces the migratory potential of UMUC1 bladder cancer cells. However, there were no significant correlations between the expression levels of the CERS2 protein with bladder cancer grade/stage or between the IC50 values of cells treated with NDV and CERS2 expression. Although the utility of CERS2 expression may be limited, its potential as an antimigration cancer therapeutic should be further examined. 1. Introduction Bladder cancer is ranked as the ninth most common cancer worldwide, and men are more than three times more likely to develop the disease as compared to women [1, 2]. Due to its high rate of recurrence and invasion, it has the highest cost of treatment per patient as compared to other malignancies [3]. Bladder cancer can be divided into two categories, nonmuscle-invasive bladder cancer and muscle-invasive bladder cancer. Nonmuscle-invasive bladder cancers account for 70% of all bladder cancers and are associated with low risk of progression and metastasis but high risk of recurrence. The treatment of nonmuscle invasive bladder cancer includes transurethral resection followed by a course of chemotherapy or immunotherapy to reduce the recurrence of the tumour [4, 5]. In contrast, muscle-invasive bladder cancers are asso- ciated with high rates of progression and metastasis and are usually treated by radical cystectomy if the tumour is organ-confined [4, 6]. To date, there are no prognostic or diagnostic biomarkers as well as predictive biomarkers of therapeutic response that are currently used in the main- stream management of bladder cancer patients [7, 8]. Hindawi Disease Markers Volume 2019, Article ID 3875147, 8 pages https://doi.org/10.1155/2019/3875147